Emergent BioSolutions Crecimiento futuro
Future controles de criterios 4/6
Emergent BioSolutions se prevé un crecimiento anual de los beneficios y los ingresos de 107.4% y 2.7% respectivamente. Se prevé que el BPA sea de grow en 107.8% al año. Se prevé que la rentabilidad de los fondos propios sea de 19.7% en 3 años.
Información clave
148.6%
Tasa de crecimiento de los beneficios
148.6%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 20.7% |
| Tasa de crecimiento de los ingresos | 3.7% |
| Rentabilidad financiera futura | 21.0% |
| Cobertura de analistas | Low |
| Última actualización | 11 Apr 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
New CEO Appointment A Clear Positive For Emergent BioSolutions
Feb 27Emergent BioSolutions: Q3 Numbers Leave Work To Be Done
Dec 18Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow
Nov 23Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial
Aug 23Financial Woes Darken Emergent BioSolutions' Outlook (Rating Downgrade)
Aug 14Emergent BioSolutions: Making A Big Bet On Narcan
Jul 21An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued
Jun 22
Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?
Apr 05Emergent Biosolutions Q4 2022 Earnings Preview
Feb 24An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued
Feb 16Emergent BioSolutions to offload travel health business to Bavarian Nordic for $380M
Feb 15Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments
Dec 07Emergent plunges 30% on quarterly earnings miss, lowers full-year guidance
Nov 09Emergent doses first participant in Phase 1 trial for Lassa virus vaccine
Sep 06Emergent BioSolutions: Now Long Through Sale Of October Put Spreads
Aug 24A Look At The Fair Value Of Emergent BioSolutions Inc. (NYSE:EBS)
Aug 13Additional 135M COVID-19 vaccine doses destroyed at Emergent BioSolutions Baltimore plant
Aug 12Emergent BioSolutions misses on top and bottom lines as it swings to quarterly loss
Aug 01Moderna 2.0: 3 Stocks To Play The Potential Monkeypox Pandemic
Jul 26Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt
Jul 26Kamada inks $11.4 M supply deal for chickenpox preventive antibody Varizig
Jul 06Emergent BioSolutions: A Top Pick For The Monkeypox Outbreak
May 29Emergent BioSolutions Inc. (NYSE:EBS) Shares Could Be 37% Below Their Intrinsic Value Estimate
May 12Emergent BioSolutions (NYSE:EBS) Has A Pretty Healthy Balance Sheet
Apr 24Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2025 | 1,126 | 67 | N/A | N/A | 1 |
| 12/31/2024 | 1,099 | -83 | -25 | 60 | 2 |
| 12/31/2023 | 1,049 | -760 | -264 | -206 | N/A |
| 9/30/2023 | 1,103 | -778 | -216 | -146 | N/A |
| 6/30/2023 | 1,072 | -602 | -602 | -280 | N/A |
| 3/31/2023 | 979 | -403 | -523 | -181 | N/A |
| 12/31/2022 | 1,118 | -212 | -394 | -34 | N/A |
| 9/30/2022 | 1,491 | 33 | -180 | 201 | N/A |
| 6/30/2022 | 1,581 | 88 | 127 | 292 | N/A |
| 3/31/2022 | 1,757 | 158 | 78 | 279 | N/A |
| 12/31/2021 | 1,774 | 220 | 96 | 320 | N/A |
| 9/30/2021 | 1,653 | 227 | 23 | 237 | N/A |
| 6/30/2021 | 1,709 | 299 | 121 | 326 | N/A |
| 3/31/2021 | 1,706 | 387 | 300 | 483 | N/A |
| 12/31/2020 | 1,577 | 306 | 385 | 537 | N/A |
| 9/30/2020 | 1,333 | 167 | 262 | 413 | N/A |
| 6/30/2020 | 1,259 | 170 | 184 | 305 | N/A |
| 3/31/2020 | 1,108 | 68 | 41 | 141 | N/A |
| 12/31/2019 | 1,106 | 55 | 91 | 188 | N/A |
| 9/30/2019 | 1,016 | 4 | -181 | -100 | N/A |
| 6/30/2019 | 878 | -18 | -15 | 77 | N/A |
| 3/31/2019 | 855 | 42 | 66 | 148 | N/A |
| 12/31/2018 | 782 | 63 | -30 | 42 | N/A |
| 9/30/2018 | 706 | 100 | 221 | 285 | N/A |
| 6/30/2018 | 681 | 113 | 96 | 146 | N/A |
| 3/31/2018 | 562 | 67 | 119 | 165 | N/A |
| 12/31/2017 | 561 | 83 | 76 | 208 | N/A |
| 9/30/2017 | 519 | 81 | N/A | 118 | N/A |
| 6/30/2017 | 512 | 68 | N/A | 110 | N/A |
| 3/31/2017 | 503 | 61 | N/A | 54 | N/A |
| 12/31/2016 | 489 | 63 | N/A | 55 | N/A |
| 9/30/2016 | 497 | 73 | N/A | 70 | N/A |
| 6/30/2016 | 512 | 94 | N/A | 148 | N/A |
| 3/31/2016 | 529 | 125 | N/A | 153 | N/A |
| 12/31/2015 | 489 | 91 | N/A | 43 | N/A |
| 9/30/2015 | 478 | 79 | N/A | 93 | N/A |
| 6/30/2015 | 457 | 59 | N/A | 67 | N/A |
| 3/31/2015 | 460 | 35 | N/A | 76 | N/A |
| 12/31/2014 | 404 | 54 | N/A | 112 | N/A |
| 9/30/2014 | 400 | 22 | N/A | 69 | N/A |
| 6/30/2014 | 351 | 14 | N/A | 50 | N/A |
| 3/31/2014 | 324 | 19 | N/A | 72 | N/A |
| 12/31/2013 | 313 | 31 | N/A | 97 | N/A |
| 9/30/2013 | 309 | 32 | N/A | 49 | N/A |
| 6/30/2013 | 287 | 25 | N/A | 36 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: EBS se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.2%).
Beneficios frente mercado: EBS se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: EBS se espera que sea rentable en los próximos 3 años.
Ingresos vs. Mercado: EBS(2.7% al año) se prevé que crezca más despacio que el mercado de US (7.9% al año).
Ingresos de alto crecimiento: EBSSe prevé que los ingresos de la empresa (2.7% al año) crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: EBSse prevé que la Rentabilidad de los fondos propios sea alta dentro de 3 años (21%)